FGFR1 and neoplasm: However, the preliminary results of phase 1 trials using selective FGFR inhibitors such as AZD4547, JnJ42756493 or BGJ398 have so far shown limited clinical benefit in FGFR aberrant tumours selected only on the basis of FGFR1 or 2 amplification (Table 3) with monotherapy response rates in the range of 5 to 25 % [13–16].